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Abstract Oridonin has attracted considerable attention in
the last decade because of its anti-cancer pharmacological
properties. This ent-kaurane diterpenoid, isolated from the
Chinese herb Rabdosia rubescens and some related spe-
cies, has demonstrated great potential in the treatment
profile of many diseases by exerting anti-tumor, anti-in-
flammatory, pro-apoptotic, and neurological effects.
Unfortunately, the mechanisms via which oridonin exerts
these effects remain poorly understood. This review pro-
vides an overview of the multifunctional effects of oridonin
as well as the reasons for its potential for investigations in
the treatment of many diseases other than cancer.
Key points
Oridonin has attracted considerable attention in the
last decade because of its effects against cancer.
Several molecular targets of Oridonin have been
identified, suggesting that oridonin may be effective
in the treatment of many other disorders in addition
to cancer (Alzheimer disease, inflammation,
immunomodulation).
Due to its multitarget activity, oridonin has potential
to be a promising compound for future drug
development.
1 Introduction
Oridonin is a famous diterpenoid isolated from the Chinese
medicinal herb Rabdosia rubescens, also known as dong
ling cao (Fig. 1). This member of the Lamiaceae family is
widely distributed in China and Japan. It is traditionally
used in Chinese medicine as an anti-tumor, anti-microbial,
anti-inflammatory, and anti-oxidant compound [1, 2]. It is
also used as a supplement in the treatment of many cancers,
such as esophagus, mammary gland, liver, and prostate
cancers and has even been a folk remedy for carcinomas of
the heart and esophagus in Hunan province [3]. Oridonin
was identified for the first time in 1967 and synthesized in
1973 [4]. It is currently one of the most important com-
pounds isolated from traditional Chinese herbal medicines
[5]. Indeed, oridonin is an ent-kaurane diterpene that has
been shown to have multiple biological activities. Among
them, the anti-cancer activity, which is reported to occur
through different cellular signaling pathways, has been
repeatedly reported. For instance, the chemopreventive and
anti-tumor effects of oridonin have been related to its
ability to interfere with several pathways involved in cell
proliferation, cell cycle arrest, and apoptosis [6].
To characterize the bioactive compounds in Rabdosia, ori-
donin was first isolated from the plant Isodon japoni-
cus (Burm. f.) H. Hara, the common name of which in
Japanese is orido, hence the chemical name [7]. The com-
pound has drawn attention for its remarkable apoptosis and
autophagy-inducing activity in cancer therapy. However, the
results of many prominent studies have proven that oridonin
possesses many other therapeutic effects, such as anti-inflam-
matory, neuroprotective, anti-bacterial, and anti-neoplastic
effects [7, 8]. For instance, oridonin attenuates b-amyloid
deposition, plaque-associated amyloidprecursor protein (APP)
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expression, and microglial activation in the brain of transgenic
mice [9]. These observations reveal the promising therapeutic
effects of oridonin, suggesting that it may be a potent alterna-
tive drug for human neurodegenerative and other inflamma-
tion-related diseases. Oridonin could also induce apoptosis
through the generation of reactive oxygen species (ROS) in
human hepatoma HepG2 cells [10]. Moreover, it has been
suggested that oridonin is able to inactivate many signaling
pathways such as protein kinase B (Akt) and ERK and activate
p38 mitogen-activated protein kinase (MAPK) and c-Jun
N-terminal kinase (JNK) signaling pathways [11, 12]. Ori-
donin can also trigger cell cycle arrest, apoptosis, and autop-
hagy in different neoplastic cell lines [13]. Despite the large
number of studies reporting the therapeutic effects of this
diterpene, the entire molecular mechanism underlying its
multi-targeted effects remains to be elucidated. This review
summarizes the considerable knowledge about the action
mechanisms of oridonin, which has been studied in recent
years.Wealso focus on highlighting theupdated data related to
multi-functional effects of oridonin inmanydiseases, aswell as
its potential application in preclinical trials.
2 Oridonin: Isolation and Structure
Oridonin is a diterpenoid (Fig. 1) isolated from the traditional
Chinese herb Rabdosia rubescens. However, many reports
also mention the isolation of oridonin from other plants and
from different countries (e.g. Isodon japonica leaves)
(Table 1). Oridonin has been reported in 12 of 74 species of
isodon, and phylogeny results indicate that its production has
arisen at least three times in the genus [14]. The production
source and harvesting region have an important impact on the
quality and quantity of oridonin produced. Therefore, Isodon
rubescens or Isodon japonicus from Hunan province are
considered to provide the best source of oridonin [14, 15].
3 Molecular Targets of Oridonin
Interest is increasing in the study of oridonin activities and
its potential effect in the treatment of many diseases [16].
Several of these studies have reported anti-proliferative,
anti-inflammatory, and anti-neoplastic effects as well as
effects on the immune system [17, 18]. The exact mecha-
nisms by which oridonin exerts these activities are not well
understood. Several proteins and receptors with which
oridonin can directly or indirectly interact have been
reported. Among the targets of oridonin, proteases, tran-
scription factors, and kinases have been characterized, and
the most important of them are discussed in this review.
3.1 Structural Proteins Targeted by Oridonin
Oridonin is reported to act on different cellular targets. The
compound regulates the protein expression of MAP-LC3
and Beclin 1 in HeLa cells [19]. Oridonin was also reported
to regulate p53 and p21 protein expressions in oridonin-
treated MCF-7 human breast cancer cells [20]. The
molecular chaperone heat shock protein (HSP)-70 1A was
identified as an oridonin target in Jurkat cells, where
HSP70 inhibition by oridonin might result in the impair-
ment of some client proteins, thus in turn affecting several
molecular pathways [6]. The expression of the anti-apop-
totic protein BCL-2 was reported to decrease in apoptotic
MCF-7 breast cancer cells treated with an oridonin
nanosuspension [21]. Experimental data showed that ori-
donin significantly reduced c-Myc protein levels in vitroFig. 1 Structure of oridonin
Table 1 Isolation of oridonin from different plant sources
Plant source Part of the plant Compounds isolated References
Rabdosia rubescens Leaves 16, 17-exo-epoxide oridonin and 11,15-0,0-diacetylrabdoternins [94]
Rabdosia nervosa Stem and leaves Lasiakaurin, ponicidin, oridonin [99]
Rabdosia japonica (Labiatae) Aerial part Oridonin, nodosin [95, 100]
Isodon japonica Leaves Epinodosin, oridonin, epinodosinol, lasiokaurin, rabdoternin A [101]
Isodon rubescens Leaves Oridonin, ponicidin, lasiokaurin, enmenol [101, 102]
Isodon serra Leaves Oridonin, lasiodonin [55]
Isodon leucophyllus Aerial parts Macrocalin B, oridonin, rosthorin, rabdoternin A [103]
Tibetan medicine Caryoteris toroetii – Oridonin, nodosin [104]
234 B. A. Owona, H. J. Schluesener
and in vivo and that this reduction was mediated by the
ubiquitin-proteasome system [22]. The compound was also
reported to increase the ratio of BAX/BCL-2 protein
expression in murine L929 cells [23]. A downregulation of
the levels of Mcl-1 and BCL-x(L) cells, but not of Bcl-2
protein, was observed in both MT-1 and RPMI8226, which
are adult T-cell leukemia and multiple myeloma cells,
respectively [24]. The downregulation of activator protein
(AP)-1 gene expression is considered to be an initial event
in the oridonin-mediated inhibition of colorectal cancer,
and AP-1 downregulation is also considered to be the ini-
tial response to treatment with oridonin [25]. Oridonin
treatment downregulated the expression of the inhibitor of
apoptosis protein (IAP) in osteosarcoma cells, and also
induced the release of cytochrome c accompanied by
activation of caspase-9, caspase-3, and cleavage of poly
(ADP-ribose) polymerase (PARP) [26]. Oridonin induced
apoptosis in A431 cells via an upregulation of the ratio of
mitochondrial proteins, BAX/BCL-2 (Table 2). In addi-
tion, the total tyrosine kinase activity of cellular mito-
chondrial proteins and expression of epidermal growth
factor receptor (EGFR) were markedly reduced after ori-
donin treatment [27]. The changes in BCL-2 and BAX
protein levels play an important role in the mechanism of
action of oridonin [5]. Oridonin has significant anti-pro-
liferation effects on HPB-ALL cells via induction of
apoptosis as well as directly causing cell necrosis by acti-
vation of caspase 3 as well as downregulation of anti-
apoptotic protein BCL-2, BCL-XL, and upregulation of
pro-apoptotic proteins BAX and BID, indicating that ori-
donin may serve as a potential anti-leukemia agent [28]. A
proteomic identification of proteins involved in the anti-
cancer activities of oridonin showed that the upregulation
of Hsp70, serine/threonine kinase receptor-associated pro-
tein (STRAP), translationally controlled tumour protein
(TCTP), Sti1, and protein phosphatase (PPase), as well as
the downregulation of heterogeneous ribonucleoprotein
(hnRNP)-E1 could be responsible for the apoptotic and G2/
M-arresting effects of oridonin [29]. Oridonin also simul-
taneously induced apoptosis and autophagy of human
multiple myeloma RPMI 8266 cells via regulation of
SIRT1 nuclear protein [30]. Finally, oridonin was reported
to induce HeLa cells apoptosis by altering balance of BCL-
2 and BAX protein expression [31]. As represented in
Table 3, experimental evidence exists of the interaction
between oridonin and many protein targets. This interac-
tion in the cell may be responsible for the different activ-
ities observed with this compound. Moreover, as
Table 2 Effect of oidonin on cellular signaling pathways
Signaling pathway Cell line Effect References
MAPK-p38 BxPC-3 Enhances anti-tumor activity of
gemcitabine
[58]
ASK1 and JNK1 HuH-6 cells Activated apoptosis signal [33]
NF kappaB and p38 Inhibition Induction of apoptosis [72]
ERK-p53 Murine fibrosarcoma L929 cells Activation [35]
PTK-Ras-Raf-JNK Murine fibrosarcoma L929 cells Inhibition [35]
Ras, JNK, and p38 Human cervical carcinoma HeLa
cells
Regulation [19]
LYN/mTOR Ph? acute lymphoblastic leukemia
cells
Inhibition of activation [52]
P65 or p50 forms of NF-kappa and its upstream
regulator I-kappa
Human breast cancer cells MCF-
10A
Decrease of expression [39]
PI3K/Akt Cervical carcinoma HeLa cell line Induction of apoptosis [73]
AP-1, NF-kappa B, and p38 Colorectal cancer cell lines Lovo
and SW480
Dowregulation [67]
Akt and MAPK Human osteosarcoma cells Induction of apoptosis [68]
P38 and JNK Human osteosarcoma cells Activation [68]
Ras/Raf/ERK A431 cells Blockage [76]
Fas/FasL signaling U937 cells Regulation [74]
ERK U937 cells Induction of cell apoptosis [75]
Insulin-like growth factor 1 receptor signaling Human melanoma A375-S2 cells Induction of cell death [76]
Caspase 9 A375-S2 cells Induction of apoptosis [77]
P53 and ERK A375-S2 cells Activation [43]
Akt protein kinase B, AP activator protein, ERK extracellular signal-regulated kinase, JNK c-Jun N-terminal kinase, MAPK mitogen-activated
protein kinase, mTOR mammalian target of rapamycin, NF nuclear factor, PI3K phosphatidylinositol-3-kinase
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Table 3 Effect of oridonin on receptors, enzymes, and protein expression
Receptor/enzyme/proteins Cellular model Effect References
P53, Bax LNCap cells Upregulation [34]
Bcl-2 LNCap cells Downregulation [34]
Androgen receptor Carcinoma A431 Downregulation [78]
Bax proteins LNCap cells Induction [79]
Bax/Bcl-2 ratio and cytochrome c HeLa cells Induction [80]
HSP 70 Jurkat cells Inhibition [81]
Nrf2 UROtsa cells Activation [37]
P16, p21, p27 and c-myc Colorectal cancer cells Regulation [38]
HO-1 Rat splenic lymphocytes Induction [18]
c-Myc Cancer cells Reduction of protein levels [22]
Pro-TNFalpha expression and IkB phosphorylation L929 fibrosarcoma cells Induction [23]
P53, Bcl-2 L929 cells Promotes phosphorylation of p53 and
increased Bax expression
[82]
AKT, FOXO transcription factor and GSK3 Human osteosarcoma cells Dephosphorylation [26]
EGFR Human laryngeal cancer cells Augmentation of apoptosis induction [83]
Fatty acid synthase Human colorectal cancer
cells
Suppression [84]
Tyrosine kinase and EGFR Human epidermoid
carcinoma A431 cells
Decrease in tyrosine kinase activity and
blockage of EGFR
[85]
Telomerase K562 cells Inhibition [86]
Bcl-2 Lung cancer cell line SPC-A-
1
Downregulation [5]
IL2, IFN gamma, IL12p40, and TNF alpha Murine splenic lymphocytes Inhibition [55]
Bax Lung cancer cell line SPC
A-1
Upregulation [5]
Caspase-3-zymogen protein, Bcl-2, and Bcl-XL HPB-ALL cells Downregulation [28]
Telomerase, Bcl-2 K562 cells Downregulation [54]
Bax K562 cells Upregulation [54]
Telomerase HL-60 cells Downregulation [87]
hTERT mRNA, and telomerase HL-60 cells Dowregulation [88]
Bcl-2/Bax ratio A549 cells Induction of ratio decrease [56]
PI3K, PKC, and ERK Macrophage-like U937 cells Activation [40]
TNF alpha, IL-1 beta Macrophage-like U937 cells Release [89]
Apaf-1, cytochrome c, and caspase-3 Gastric cancer cell line HGC-
27
Induction [90]
p-JNK, p-p38, p-p53, and p21 HepG2 cells Incretion [42]
B1/p-Cdc2 (Tyr15) complex HepG2 cells Increase [42]
Hsp70.1, STRAP, TCTP,Sti1 and PPase HepG2 cells Upregulation [29]
hnRNP-E1 HepG2 cells Downregulation [29]
Bcl-2/Bax ratio, caspase-8, NF-kappa B(p65),
IKKalpha, phospho-mTOR
Human breast cancer cells Reduction [57]
Cleaved PARP, Fas, and PPAR gamma Human breast cancer cells Increase [57]
NO, TNF alpha, IL6 LPS-activated microglia Inhibition [45]
Nucleoporin 88 and 214 OCIM2 acute
erythroleukemia cells
Protection from apoptosis [91]
SIRT1 Human multiple myeloma
cells
Regulation [30]
Raf-1, JNK, and p-JNK HeLa cells Induction [92]
BAFF mice Inhibition [93]
BIM Melanoma OCM-1 and
MUM2B cell lines
Upregulation [110]
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represented in Fig. 2, the connections between the different
proteins affected by oridonin are crucial for the compre-
hension of its mechanism of action.
3.2 Regulation of Transcription Factors
and Signaling Pathways by Oridonin
The activation of many transcription factors and signaling
pathways is reported to be crucial in the mechanism of
action of oridonin. Oridonin induced growth inhibition and
apoptosis in cultured HuH-6 cells through ASK1/JNK1
signaling pathways [32], which enhances the understanding
of the molecular mechanisms of oridonin in hepatoblas-
toma management [33]. Oridonin upregulated p53 and
BAX and downregulated BCL-2 expression in a dose-de-
pendent manner in human prostate cell lines DU-145 [34].
Oridonin induction of apoptosis in L929 cells is regulated
by ROS-mediated signaling pathways, and oridonin-in-
duced autophagy may block apoptosis by upregulating p38
and nuclear factor (NF)-kappa B activation [35]. The
autophagy induced by oridonin in HeLa cells was also
investigated; results showed that the oridonin-induced
autophagic process was negatively regulated by Ras but
positively regulated by P38 and JNK MAPKs [19]. Ori-
donin also downregulated the phosphorylation of ERK,
whereas those of JNK and P38 were upregulated in human
breast cancer MCF-7 cells [36]. The transcription factor
nuclear factor erythroid 2-related factor 2 (Nrf2) is a
Table 3 continued
Receptor/enzyme/proteins Cellular model Effect References
Fatty acid synthase Melanoma OCM-1 and
MUM2B cell lines
Downregulation [110]
PARP BXPC-3 cells Induction [111]
AKT protein kinase B, BAFF B-cell activating factor, Bcl B-cell lymphoma, EGFR epidermal growth factor receptor, FOXO forkhead box O,
GSK3 glycogen synthase kinase 3, hnRNP heterogeneous ribonucleoprotein, HSP heat shock protein, hTERT human telomerase reverse tran-
scriptase, IFN interferon, IL interleukin, mRNA messenger RNA, mTOR mammalian target of rapamycin, NO nitric oxide, PARP poly (ADP-
ribose) polymerase, PI3 phosphatidylinositol-3, PKC protein kinase 3, PPAR peroxisome proliferator-activated receptor, PPase protein phos-
phatase, STRAP serine/threonine kinase receptor-associated protein, TCTP translationally controlled tumour protein, TNF tumor necrosis factor
Fig. 2 An overview of the
molecular targets of oridonin
and potential therapeutic
effects. The interaction of






positively (indicated by green
star) or negatively (indicated by
yellow star). Thereby, a
potential therapeutic effect of
oridonin in the treatment of
many diseases can be
emphasized
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critical regulator of the cellular antioxidant response and
xenobiotic metabolism. Oridonin activates the Nrf2 sig-
naling pathway at a low subtoxic dose and is able to sta-
bilize Nrf2 by blocking Nrf2 ubiquitination and
degradation, leading to accumulation of the Nrf2 protein
and activation of the Nrf2-dependent cytoprotective
response [37]. Oridonin induced apoptosis and senescence
in colorectal cancer cells by increasing histone hyper-
acetylation and regulation of p16, p21, p27, and c-myc
[38]. The NF-kappa B-inhibiting capacity of oridonin has
been studied in several different cell types. For instance,
decreases in p6 or p50 forms of NF-kappa B and its
upstream regulator I-kappa B were found in oridonin-
treated human cancer cells MCF-7 [39]. Oridonin also
inhibits the proliferation of cells from lymphoid malig-
nancies in association with blockade of the NF-kappa B
signaling pathways [24]. NF-kappa B, AP-1, and P38 were
all found to be downregulated in vivo after 4 weeks of
treatment with oridonin in the colorectal cancer cell line
Lovo, indicating that the downregulation of AP-1 could be
an initial response to treatment by oridonin and this regu-
lation in turn affects the expression of NF-kappa B and
MAPK pathways, thereby inhibiting tumor growth [25].
The enhancement of phagocytosis of apoptotic bodies in
human macrophage-like U937 cells by oridonin has been
reported to occur through an activation of phosphatidyli-
nositol-3 kinase (PI3K), protein kinase 3 (PKC), and ERK-
dependent signaling pathways [40]. Another study on the
phagocytic activity demonstrated that Ras/Raf1/ERK sig-
naling pathway-dependent I-kappa B-alpha degradation,
resulting in NF-kappa B activation, participates in regula-
tion of oridonin-enhanced phagocytosis [41]. Oridonin was
reported to induce G2/M cell cycle arrest and apoptosis by
increasing the expression levels of p-JNK, p-p38, p-p53,
and p21 and elevating the level of cyclin B1/p-Cdc2
(Tyr15) complex in HepG2 cells [42]. Oridonin induced
A375-S2 cell apoptosis by activating in parallel p53 and
ERK pathways, simultaneously promoting the release of
cytochrome c into the cytosol, resulting in apoptotic cell
death [43].
4 Immunomodulatory Effects
Among the diverse activities of oridonin, its effect on the
immune system and on pro-inflammatory mediators is one
of the most important. Oridonin was reported to promote
differentiation of cluster of differentiation (CD)-4?/CD25?
T-regulatory (Treg) cells, and to modulate the T-helper
(Th)-1/Th2 balance in rat splenic lymphocytes [18]. An
investigation of the effect of oridonin on intracellular tumor
necrosis factor (TNF)-alpha expression revealed that the
compound augments endogenous pro-TNF alpha expression
and its upstream protein IkB phosphorylation [23]. Oridonin
also blocked TNF-alpha and lipopolysaccharide-stimulated
NF-kappa activity in Jurkat cells as well as in RAW264.7
murinemacrophages [24]. Oridonin was reported to enhance
phagocytosis of apoptotic bodies by activating PI3K-, PKC-,
and ERK-dependent pathways in human macrophage-like
U937 cells [40]. Another study demonstrated that Ras/Raf/
ERK signaling pathway-dependent Ikappa-Balpha degra-
dation, resulting in NF-kappa B activation, participates in
regulation of oridonin-enhanced phagocytosis, and that one
of its effector functions is to induce the synthesis of inter-
leukin (IL)-1 beta, which partially contributes to its phago-
cytic activity [41]. Oridonin facilitated the phagocytic
activity against apoptotic cells through TNF alpha and IL-1
beta release, thereby contributing to its anti-tumor activities
[44]. Moreover, oridonin pretreatment inhibits the release of
pro-inflammatory mediators, including nitric oxide, TNF
alpha, IL-1 beta, and IL-6, resulting in the inhibition of the
DNA-binding activity of NF-kappa B [45]. Oridonin is also
reported to be a potential modulator for trinitrobenzene
sulfonic acid-induced colitis and other Th1/Th17-mediated
inflammatory diseases [108].
5 The Role of Reactive Oxygen Species
in Oridonin Activity
ROS are important signaling molecules involved in
immune defenses, cell proliferation, and cell repair. Ori-
donin has been shown to increase intracellular hydrogen
peroxide levels and reduce the glutathione content in col-
orectal cancer cells (Table 4). These effects were important
in oridonin-induced apoptosis and senescence in these cells
[46]. Another study showed that oridonin stimulates
mitochondrial transmembrane permeabilization in a ROS-
dependent manner, and these ROS produced are responsi-
ble for the oridonin-induced HepG2 apoptosis through p53,
MAPK, and mitochondrial signaling pathways [47]. The
growth inhibitory activity of oridonin was studied in L929
cells, where a rapid generation of ROS was noted as being
triggered by oridonin, and subsequently upregulation of
phospho-p53 expression and increased expression ratio of
BAX/BCL-2 was observed. In this study, it was demon-
strated that oridonin induced cell death in murine
fibrosarcoma L929 by enhancing ROS generation [48]. It
was also demonstrated that the hydroxyl radical OH()
plays a pivotal role in oridonin-induced apoptosis and
autophagy in human epidermoid carcinoma A431 cells
[49]. Oridonin was reported to cause a modest level of ROS
generation in U937 cells, with hydrogen peroxide (H2O2)
and hydrogen free radical OH() as the major types. These
two types of ROS were positive regulators involved in
oridonin-enhanced engulfment of apoptotic cells. H2O2 and
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OH generation also activated PI3K-Akt and phospholipase
C gamma-protein kinase C (PLC gamma)-Ras-Raf-ERK
signaling pathways, which are essential for oridonin-in-
duced apoptosis [50]. Nitric oxide was reported to augment
oridonin-induced efferocytosis (phagocytosis of apoptotic
cells) in human histocytic lymphoma U937 cells via
autophagy and the NF-kappa B-cyclooxygenase-2-IL-1beta
pathway [51]. Oridonin was reported as inducing apoptosis
and autophagy of human multiple myeloma RPMI8266
cells via the regulation of intracellular ROS generation
[30].
6 Oridonin: Top Interacting Genes
Oridonin is considered to be a safe and multi-targeted
compound and has been reported to interact with many
genes. We used the Comparative Toxicogenomics Data-
base to find the top interacting genes, and observed that
HMOX1, BLC2, CASP3, IFNG, IL10, PARP1, and TGFB1
are the most important (Table 5). HMOX1 (heme oxyge-
nase 1, EC 1.14.99.3) is an essential enzyme in heme
catabolism that cleaves heme to form biliverdin. Oridonin
is reported to increase the activity of HMOX1 messenger
RNA (mRNA) and protein in rat splenic lymphocytes [18].
Oridonin is also reported to downregulate anti-apoptotic
protein BCL-2 expression in many cancer cells [5, 24, 28,
34, 52–54]. Oridonin also inhibits/decreases the expression
of IL2 protein in rat splenic lymphocytes and in BALB/c
mouse splenic lymphocytes [18, 55]. Oridonin decreased
the expression of IFN gamma (IFNG) and increased the
expression of IL10 protein [18]. Oridonin increases the
cleavage of caspase-3 protein [26, 56].
PARP1 is an enzyme that in humans is encoded by the
PARP1 gene, which is involved in differentiation, prolif-
eration, and tumor transformation. Oridonin was reported
to increase the cleavage of PARP1 protein in highly
metastatic human breast cancer cells [57]. Transforming
growth factor beta 1 (TGFB1) is a polypeptide member of
the TGFB superfamily of secreted cytokines that perform
many cellular functions, including apoptosis, cell differ-
entiation, and cell proliferation. In humans, TGFB1 is
encoded by the TGFB1 gene, and oridonin is reported to
increase expression of the TGFB1 protein [18].
Table 4 Effect of oridonin on cellular models
Effect Cell type/model References
Cytotoxic effect Human Hep G2, COLO 205, MCF-7 and HL-60 cancer cells [94]
Cytotoxicity HL-60, HO-8910, and A-549 human tumor cells [95]
Anti-proliferative activity Human cell lines derived from prostate (DU-145, LNCaP), breast
(MCF-7), and ovarian (A2780 and PTX10) cancers
[34]
Induction of apoptosis and autophagy Murine fibrosarcoma L929 cells [72]
Intracellular ROS generation, lipid peroxidation as well as
decrease in SOD and glutathione activities
Murine fibrosarcoma L929 cells [72]
Induces G2/M arrest and apoptosis Murine fibrosarcoma L929 cells [35]
Induction of apoptosis and autophagy HeLa cells [80]
Confers protection against arsenic-induced toxicity UROtsa cells [37]
Growth inhibition and inhibition of apoptosis MCF-/breast cancer cells [21]
Induce apoptosis and senescence and increase histone hyper
acetylation
Colorectal cancer cells [38]
Induces apoptosis and senescence by increasing H2O2 and
glutathione depletion
Colorectal cancer cells [46]
Inhibition of proliferation MKN45 cells [96]
Induced S/G2M arrest and G1/S block MCF-7 cells [39]
Promotes differentiation CD4?/CD25? T-reg [18]
Induced TGF-beta and IL-10
Inhibited IL-2 and IFN-gamma
Rat splenic lymphocytes [18]
Induction of G(2)M phase arrest and apoptosis Human laryngeal carcinoma cells [97]
Enhance phagocytosis of apoptotic bodies Human macrophage-like U937 cells [40]
Induction of cell motility Murine melanoma K1735M2 cells [98]
Induction of G2/M cell cycle arrest HepG2 cells [42]
CD cluster of differentation, IFN interferon, IL interleukin, ROS reactive oxygen species, SOD superoxide dismutase, TGF transforming growth
factor, T-reg T-regulatory cells
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7 Adjuvant/Synergistic Effects
In order to increase the effect of oridonin, it has been com-
bined with other compounds with reported therapeutic
effects. Oridonin could potentiate the effects of gemcitabine
in PaCa pancreatic cancer cells through the MAPK-p38
signaling pathway [58]. An oridonin and arsenic trioxide
combination were reported to enhance tumor-suppression
activity in a human hepatocellular carcinoma (HCC) model
comparedwith single agent treatment in vivo, demonstrating
that oridonin can sensitize HCC cells to As2O3 treatment
and therefore facilitate the optimization of As2O3 therapy
for HCC patients [59]. Oridonin in combination with ima-
tinib revealed a synergetic anti-leukemia effect in Ph? acute
lymphoblastic leukemia cells in vitro by inhibiting the acti-
vation of the LYN/mammalian target of rapamycin (mTOR)
signaling pathway [52]. A promising combined activity of
oridonin and wogonin was reported in advanced-stage
ovarian cancer cells [60]. The synergistic effect of oridonin
and cisplatin on cytotoxicity and DNA cross-link against
mouse sarcomaS180 cells in culturewas reported to increase
after combining the two drugs [61].
8 Oridonin Formulation and Bioavailability
Despite the promising effects of oridonin, its clinical
development has been hampered by its limited aqueous
solubility and bioavailability [62]. Moreover, the oridonin
solution is not stable [63]. The development and application
of oridonin is also reported to be limited by its rapid plasma
clearance. To solve this problem, many different approaches
have been developed to increase the solubility and
bioavailability of oridonin. PEGylated oridonin linked with
succinic acid (SA) as a spacer moiety (PEG-SA-ORI) was
synthesized [64]. All polymeric conjugates obtained showed
satisfactory aqueous solubility, and in vitro studies showed
that the drug solubility increased, suggesting that PEGyla-
tion could be a promising method to increase the efficacy of
oridonin. Oridonin nanosuspension was reported to be more
effective than free oridonin on G(2)/M cell cycle arrest and
apoptosis in the human pancreatic cancer PANC-1 cell line
[65]. The drug carrier monomethoxy poly(ethylene glycol)-
poly(epsilon-caprolactone) (MPEG-PCL) was used to
increase the water solubility of oridonin and the prepared
oridonin micelles obtained presented great potential for
direct intravascular administration [66]. A self-microemul-
sifying drug-delivery system (SMEDDS) was developed to
enhance the bioavailability of oridonin. The absorption of
oridonin from SMEDDS showed a 2.2-fold increase in rel-
ative bioavailability compared with that of the suspension,
demonstrating the promising use of SMEDDS for the oral
delivery of oridonin [67]. Oridonin-loaded nanoparticles
coated with galactosylated chitosan (ORI-GC-NP) was
reported as a promising intravenous drug-delivery system for
oridonin that could be developed as an alternative to the
conventional oridonin preparations [68]. In a recent study, a
novel biotin-modified nanostructured lipid carrier was
developed to enhance the bioavailability of oridonin [109].
9 Oridonin as a Therapeutic Agent in Many
Diseases
Oridonin could be associated with the treatment of many
diseases via interaction with many inference networks. The
Comparative Toxicogenomics Database reports 232 dif-
ferent diseases that could be directly or indirectly associ-
ated with oridonin and the different inference networks
involved. Based on these observations, the compound
really needs to be investigated for the treatment of many
other diseases aside from cancer. For instance, a recent
publication showed oridonin was able to ameliorate neu-
ropathological changes and behavioral deficits in a mouse
model of cerebral amyloidosis by attenuating b-amyloid
deposition, plaque-associated APP expression, and micro-
glial activation in the brain of transgenic mice [9]. Ori-
donin was shown to lower pulmonary artery pressure in rats
[68]. It is therefore presented as a new research target for
future and promising investigations.
10 Structure/Activity Relationship
The chemical structure of oridonin has been modified in
some studies to increase its therapeutic effects. Therefore,
overcoming synthetic challenges of oridonin A-ring struc-
tural diversification is attracting high levels of interest.
Regio and stereoselective installation of azides and 1, 2,
3-triazoles at the C-1, C-2, or C-3 position was shown to
Table 5 Oridonin top interacting genes
Interacting gene Interaction References
IL10 Increases expression of the protein [18]
IL2 Increases expression of the protein [18]
IFNG Decreases expression of the protein [55]
HMOX1 Increases mRNA expression [18]
HMOX1 Increases expression of the protein [18]
CASP3 Increases cleavage of the protein [105]
BCL2 Decreases expression of the protein [106]
PARP1 Increases cleavage of the protein [20]
TGFB1 Increases expression of the protein [107]
BCL B-cell lymphoma, HMOX heme oxygenase, IFNG interferon
gamma, IL interleukin, mRNA messenger RNA, PARP poly (ADP-
ribose) polymerase, TGFB transforming growth factor B
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improve the effect of oridonin [69]. New nitrogen-enriched
oridonin analogs obtained by rationally modifying the
structure of oridonin with thiazole-fused in the A-ring
through an efficient protecting group-free synthetic strat-
egy were shown to enhance the anti-cancer profile, as well
as to improve the water solubility [62].
Oridonin was reported to exhibit moderate effects against
highly aggressive cancers. Therefore, efficient and regiose-
lective enone construction strategies have been established.
With oridonin ring A-based diverse constructions of enone
functionality, novel dienone analogs were produced and
reported effective against highly aggressive breast cancer by
inducing apoptosis [70]. The structure-activity relationship
of six ent-kaurane diterpenoids, including oridonin, on
cytotoxicity and DNA damage potential against three human
tumorHepG2, GLC-82, andHL-60 cell lines was reported. It
was found that exo-methylene cyclopentanone in the
molecular structure is important in maintaining the cyto-
toxicity and DNA damage potential of oridonin.With an OH
group at positionC1, oridonin exhibited a higher cytotoxicity
and DNA damage potential on the tumor cells than
lasiokaurin (OAc group at position C1) [71].
11 Conclusion
Oridonin has shown promising effects in the modulation of
molecular pathways in different cell models. Several
molecular targets have already been identified, which can
partially explain the broad range of in vitro biological
effects of the compound. The compound has also shown
promising effects in the treatment of diseases other than
cancer. Therefore, further studies aiming at investigating
the effect of oridonin in many other disease treatments
could be promising.
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